Keeping the retina's gene-control system working
Homeostasis of the Retinal Epigenome
This work focuses on how a protein called H3.3 helps retinal cells grow and survive, which could matter for people at risk of vision loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11145008 on NIH RePORTER |
What this research studies
From a patient's perspective, the team uses mice engineered to lack the histone variant H3.3 in the developing eye to see which retinal cell types are lost and how vision-related genes change. They map chromatin accessibility (for example with ATAC-seq) and measure gene activity to learn where H3.3 is needed to keep important genes turned on. The researchers will characterize the eye changes in detail and connect those changes to specific gene-control mechanisms. The goal is to reveal how defects in H3.3 could lead to retinal degeneration and point to possible targets for future therapies.
Who could benefit from this research
Good fit: People with inherited retinal degenerations, unexplained progressive retinal cell loss, or syndromic conditions linked to histone (H3.3) mutations would be the most relevant group.
Not a fit: People whose vision loss is due to non-retinal causes (for example untreated cataract or optic nerve injury) or long-standing, irreversible damage are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could reveal causes of some retinal degenerations and point to new biological targets for treatments to prevent or slow vision loss.
How similar studies have performed: Epigenetics and chromatin-mapping methods have previously identified important roles for histone changes in development, but focused studies of H3.3 in retinal development are relatively new and have limited direct translation to human treatments so far.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ruzycki, Philip Andrew — Washington University
- Study coordinator: Ruzycki, Philip Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.